Resistant PTSD May Have Met Its Match in Mushrooms

In a small clinical trial, nine of 12 veterans with treatment-resistant PTSD no longer met the diagnostic criteria for the disorder one month after completing psilocybin-assisted therapy. The treatment combined two doses of synthetic psilocybin, the active ingredient in magic mushrooms, with 14 to 16 hours of structured psychotherapy.

The Ohio State pilot study was the first U.S. clinical trial of psilocybin-assisted therapy in military veterans with treatment-resistant PTSD. Participants had severe symptoms that conventional treatments had failed to relieve. Their clinician-rated PTSD scores fell by an average of 27.5 points, a substantial improvement in a group that had already spent years looking for relief.

The 11-week protocol included eight hours of preparation, two psilocybin sessions at doses of 15 mg and 25 mg and six to eight hours of follow-up therapy. No serious adverse events occurred, and suicidal ideation did not increase. The most common side effect was a mild headache.

But the drug may not be the whole story.

Researchers found that symptoms were already improving during the preparation phase, before participants received psilocybin. The largest reductions came afterward. That raises a question the psychedelic therapy field is still trying to answer: How much of the benefit comes from the drug, how much from psychotherapy and how much from the combination?

The trial had no control group, and 12 participants are not enough to establish that the treatment works reliably. Researchers are now studying whether the improvements last and hope to conduct a larger randomized trial.

For now, the result is a promising signal from a treatment that asks medicine to take both the molecule and the therapeutic process seriously.

Read the full story at Neuroscience News, July 30, 2026

Hot Take: Even if the benefit isn't entirely from the mushrooms, taking a little trip with American Beauty as the soundtrack seems like it would do the soul some good.